TradeFlare's AI research teams analysed ZBIO on 6 market nights between May 1, 2026 and August 17, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 17, 2026 | BUY | $29.51 | — / — | +3.8% | +4.7% | The market regime is neutral, and the stock's directional teams are not sufficiently bullish to warrant a buy. |
| August 14, 2026 | BUY | $29.20 | — / — | +9.4% | +8.1% | Positive INDIGO trial results could drive future development. |
| July 10, 2026 | BUY | $29.43 | — / — | +2.8% | +12.8% | Promising Phase 3 data for obexelimab in IgG4-RD. |
| July 9, 2026 | BUY | $28.76 | — / — | -4.0% | +9.3% | The market regime is neutral, and while ZBIO shows a post-earnings drift, the technicals are neutral and testing resistance, with a high risk score and no bullish directional teams. |
| July 2, 2026 | BUY | $28.00 | $33.60 / $23.80 | +5.5% | +15.5% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| May 1, 2026 | BUY | $19.32 | — / — | +1.4% | -6.2% | Positive clinical trial data for ZBIO's pipeline drugs. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.